Does a common MTHFR mutation leave most people unable to process folate, and does Brecka's methylated-vitamin protocol fix this to extend healthspan?
Claim attributed to Gary Brecka , Self-described "human biologist" and co-founder of 10X Health System; holds two undergraduate biology degrees, no medical degree or clinical license, and a background as a life-insurance mortality analyst. 10X Health sells the genetic test and methylated supplements his protocol recommends.
Methylfolate reliably lowers homocysteine, a blood marker, but the disease link the pitch rests on was directly tested and failed. The variant is real and common; "most people cannot process folate" and "extends healthspan" overstate a minor modifier into a sell-the-test-then-the-supplement root cause.
Correcting a true deficiency with methylfolate is fine; telling most people they cannot process folate, and that a $600 test plus supplements will extend their healthspan, is not what the evidence says.
What it’s supposed to target
- MTHFR gene variant (C677T)
- Folate methylation
- Homocysteine
- Methylated B-vitamins
Gary Brecka's signature pitch starts from a real gene. The MTHFR enzyme helps convert folate into its active, methylated form, and common variants such as C677T modestly lower that enzyme's activity, which can nudge up homocysteine. From there the theory runs: if your genetics blunt methylation, you cannot use ordinary folate well, this quietly drives disease, and the fix is to bypass the bottleneck with pre-methylated B-vitamins (methylfolate, methylcobalamin). It is a tidy “find the root cause in your DNA, then supplement it” narrative.
The science does not carry the weight put on it. MTHFR variants are common and usually modest in effect, and major genetics bodies recommend against routine MTHFR testing precisely because the result rarely changes care; the once-feared disease links largely did not hold up. Methylated B-vitamins matter mainly for genuine deficiency, not as a population-wide “root cause” fix. Two further problems: Brecka's billed “human biologist” credentials are widely disputed, and his company sells the very tests and supplements the protocol recommends, a direct conflict. Correcting a real deficiency is sound; the leap to “most people need this to optimize healthspan” is not.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
The variant would have to leave most people genuinely unable to process folate. HOLDS ONLY WEAKLY: it is common but a modest modifier, and folate-replete carriers methylate fine.
The resulting high homocysteine would have to drive disease. FAILS: meta-analyses disproved the coronary-heart-disease and venous-thrombosis links.
Supplementing methylfolate would have to prevent that disease and extend healthspan. FAILS for disease (RCTs show no event reduction); UNTESTED for healthspan.
What the evidence actually shows
The mainstream verdict is against routine testing and against the disease link
The ACMG 2013 practice guideline concludes MTHFR polymorphism testing has "minimal clinical utility" and "should not be ordered as a part of a routine evaluation for thrombophilia," citing meta-analyses that disproved the hyperhomocysteinemia-coronary-heart-disease association and found no link between MTHFR status and venous thromboembolism. A genetic-counseling review (Levin & Varga 2016) reinforces that finding a variant does not change medical care and, notably, that there is no published evidence that 5-MTHF is preferable to ordinary folic acid, undercutting the methylfolate-superiority pitch itself.
Lowering the biomarker does not deliver the promised outcome
A 2025 cardiovascular review confirms B-vitamin supplementation reliably lowers homocysteine but failed to reduce major cardiovascular events across large RCTs (HOPE-2, NORVIT, VITATOPS), and that the AHA does not recommend routine homocysteine screening or B-vitamin supplementation for prevention. A 272-person RCT confirms the legitimate kernel: methylfolate lowers homocysteine most in TT carriers, but reports only biomarker endpoints, no clinical or healthspan benefit. The chain breaks between marker and disease.
Studies, graded, and who paid
True: the homozygous TT genotype runs roughly 8 to 20% in many groups and cuts in-vitro enzyme activity by about 70% (residual ~30% of normal); the milder CT heterozygote is the ~30 to 40% reduction. Either way it is a minor modifier, not an on/off switch.
Overstated and largely disproven: meta-analyses found no MTHFR link to coronary heart disease or venous clots; folate-replete carriers methylate adequately.
Methylfolate lowers the biomarker, but RCTs show lowering homocysteine does not cut cardiovascular events, and no trial shows healthspan benefit.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 1 | ACMG practice guideline (Hickey 2013) | Clinical practice guideline / evidence review | Synthesis of multiple meta-analyses | Independent Professional-society guideline (ACMG); no commercial sponsor. | Guideline, not new primary data; focused on thrombophilia/CHD endpoints. |
| 2 | Homocysteine in the cardiovascular setting (2025 review) | Narrative review of large RCTs | HOPE-2 ~5,500; NORVIT ~3,700; VITATOPS ~8,000 | Independent Academic review of publicly funded RCTs; no industry sponsor identified. | Narrative, not a fresh meta-analysis; HOPE-2 did show a stroke-incidence drop though the primary CVD endpoint was null. |
| 3 | Methylfolate/folinic acid RCT in healthy adults (2023) | Randomized controlled trial (biomarker endpoint) | 272 adults, 3 months | Funding unknown Funding not stated in abstract; treat as unverified. | Biomarker-only (homocysteine); no clinical or healthspan outcomes; short duration. |
| 6 | MTHFR genetic-counseling review (Levin & Varga 2016) | Evidence-based clinical review | Literature synthesis | Independent Peer-reviewed journal; no industry sponsor identified. | Publisher full text paywalled; thrust confirmed via PubMed, exact quotes not verbatim-verified. |
The pitch conflates moving a lab number (homocysteine) with preventing disease, a surrogate-endpoint substitution that the randomized evidence specifically rejects.
Unproven ≠ disproven
The bundled 10X Health protocol as a consumer healthspan product has no completed long-term trial either way, so that specific promise is unproven; the cardiovascular and clotting disease links, by contrast, are disproven, not merely untested.
Where claim and evidence diverge
No independent RCT tests the complete protocol for healthspan, and lifespan endpoints need very long, costly trials, so the claim leans on a biomarker already shown not to predict the promised outcomes.
The money trail
Brecka co-founded and is "chief human biologist" of 10X Health, which sells the genetic test (reported ~$600) that operationalizes the claim and then the methylfolate/methylcobalamin recommended afterward.
Independent reviewers describe the pattern as identify a problem via the proprietary test, then sell the solution: "watch what they say, then watch what they sell."
The honest read
Real variant, real biomarker shift, wrong conclusion: the disease and healthspan promises were tested or remain untested, the seller profits at both steps, and folic acid (which broad audiences are told to avoid) still prevents neural-tube defects in pregnancy.
What would change this verdict
An independent RCT showing the methylated-vitamin protocol reduces hard clinical endpoints or extends healthspan, not just lowers homocysteine.
Reversal of the consensus, e.g. ACMG/AHA endorsing routine MTHFR testing or B-vitamins for disease prevention based on new outcome trials.
Sources
- Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153-156. PMID 23288205.
- Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do. Review, 2025. PMC12564181.
- Effects of folinic acid and l-methylfolate on serum homocysteine in healthy adults. Clin Nutr ESPEN. 2023. PMID 38056998.
- foodfacts.org, Gary Brecka fact-check hub (aggregating Science Feedback reviews).
- Beres D. The slippery science of Gary Brecka. re:frame (Substack), 2024.
- Levin B, Varga E. MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature. J Genet Couns. 2016;25(5):901-911. PMID 27130656.
People also ask
- Does the MTHFR C677T mutation mean you can't process folate?
- No, that overstates it. The C677T variant is real and common (homozygous TT roughly 8 to 20 percent in many groups). The TT genotype cuts in-vitro enzyme activity by about 70 percent (the milder CT heterozygote is the 30 to 40 percent reduction), but it is a minor modifier, not an on/off switch: folate-replete carriers methylate adequately.
- Does the MTHFR mutation cause disease?
- Largely disproven. Meta-analyses found no link between MTHFR and coronary heart disease or venous clots. The variant is a minor modifier rather than a driver of disease, despite being framed as a root cause.
- Do methylated B-vitamins like methylfolate extend healthspan?
- Unproven. Methylfolate reliably lowers homocysteine, a blood marker, but randomized trials show that lowering homocysteine does not cut cardiovascular events, and no trial shows a healthspan benefit. The biomarker shift does not predict the promised outcomes.
- Should I avoid folic acid if I have MTHFR?
- Be careful with that advice. Folic acid still prevents neural-tube defects in pregnancy, even though broad audiences are often told to avoid it. Correcting a true deficiency with methylfolate is fine, but the sweeping claims go beyond the evidence.
Part of our guide: Longevity influencers and protocols, fact-checked
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.